| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041866258 |
| P356 | DOI | 10.1038/KI.2012.403 |
| P932 | PMC publication ID | 4292921 |
| P698 | PubMed publication ID | 23254903 |
| P5875 | ResearchGate publication ID | 233958146 |
| P50 | author | George P. McCabe | Q113997858 |
| Berdine R. Martin | Q113997896 | ||
| Meryl E Wastney | Q114783749 | ||
| Connie Weaver | Q48005905 | ||
| Kathleen M Hill Gallant | Q90099490 | ||
| Sharon M Moe | Q91339340 | ||
| P2093 | author name string | Munro Peacock | |
| P2860 | cites work | A Biometric Study of Human Basal Metabolism | Q24522696 |
| Role of phosphorus in the pathogenesis of secondary hyperparathyroidism | Q31833179 | ||
| Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? | Q33684149 | ||
| Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease | Q34557934 | ||
| KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). | Q34994912 | ||
| Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease | Q35099518 | ||
| Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets | Q35962450 | ||
| CKD-mineral and bone disorder: core curriculum 2011. | Q37697926 | ||
| Intestinal absorption of calcium and the effect of renal insufficiency | Q39888039 | ||
| Changing phosphorus content of the U.S. diet: potential for adverse effects on bone | Q40994143 | ||
| Polyethylene glycol 4000 as a continuously administered non-absorbable faecal marker for metabolic balance studies in human subjects | Q43249543 | ||
| Renal osteodystrophy in end-stage renal failure | Q44741181 | ||
| Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values | Q45119840 | ||
| Serum phosphate levels and mortality risk among people with chronic kidney disease | Q45198981 | ||
| K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease | Q46286369 | ||
| Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients | Q46631801 | ||
| Renal function and risk of hip and vertebral fractures in older women. | Q51924728 | ||
| Net intestinal absorption of calcium in patients with chronic renal failure. | Q52946276 | ||
| The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer | Q57221098 | ||
| Exercise and calcium supplementation: effects on calcium homeostasis in sportswomen | Q57221192 | ||
| Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis | Q57227542 | ||
| Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3 | Q67063586 | ||
| Hyperphosphatemia | Q67583540 | ||
| Study of intestinal absorption of calcium in patients with renal failure | Q69351455 | ||
| Renal impairment and its effects on calcium metabolism in elderly women | Q70469059 | ||
| Differences in calcium kinetics between adolescent girls and young women | Q71405039 | ||
| A postulate to aid in model building | Q72681179 | ||
| Increased risk of hip fracture among patients with end-stage renal disease | Q73969374 | ||
| Balancing needs, efficiency, and functionality in the provision of modeling software: a perspective of the NIH WinSAAM Project | Q77441022 | ||
| Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease | Q79337877 | ||
| The case against calcium-based phosphate binders | Q80797026 | ||
| The effect of soy protein and soy isoflavones on calcium metabolism in postmenopausal women: a randomized crossover study | Q81627850 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phosphorus | Q674 |
| calcium carbonate | Q23767 | ||
| chronic renal insufficiency | Q736715 | ||
| P304 | page(s) | 959-966 | |
| P577 | publication date | 2012-12-19 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease | |
| P478 | volume | 83 |
| Q92346687 | 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report |
| Q38741675 | A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs? |
| Q45712908 | A balanced view of calcium and phosphate homeostasis in chronic kidney disease |
| Q37614180 | A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. |
| Q64933828 | A prospective study of the influence of the skeleton on calcium mass transfer during hemodialysis. |
| Q38587575 | Advances in pharmacotherapy for hyperphosphatemia in renal disease |
| Q38195297 | Are calcium-based phosphate binders ever preferable in dialysis patients? |
| Q55024096 | Association between Dietary Intake and Coronary Artery Calcification in Non-Dialysis Chronic Kidney Disease: The PROGREDIR Study. |
| Q38685859 | Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function. |
| Q47738927 | Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. |
| Q92641120 | Calcium |
| Q33720411 | Calcium Balance in Chronic Kidney Disease |
| Q48038085 | Calcium Homeostasis in Health and in Kidney Disease |
| Q38941532 | Calcium as a cardiovascular toxin in CKD-MBD. |
| Q33837633 | Calcium balance and negative impact of calcium load in peritoneal dialysis patients |
| Q38240989 | Calcium supplementation in chronic kidney disease |
| Q88814822 | Chronic kidney disease: KDIGO CKD-MBD guideline update: evolution in the face of uncertainty |
| Q35067500 | Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease |
| Q37256525 | Delayed progression to dialysis with early and intensive management of predialysis chronic kidney disease: a case-based approach |
| Q35841012 | Deregulated Renal Calcium and Phosphate Transport during Experimental Kidney Failure |
| Q38725971 | Dietary Phosphorus Intake and the Kidney. |
| Q24187142 | Dietary interventions for mineral and bone disorder in people with chronic kidney disease |
| Q37333243 | Early chronic kidney disease-mineral bone disorder stimulates vascular calcification |
| Q99584598 | Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial |
| Q57214099 | Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats |
| Q37416887 | Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. |
| Q58087313 | Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism |
| Q92206362 | Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial |
| Q37613856 | Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia |
| Q90101217 | FGF23 at the crossroads of phosphate, iron economy and erythropoiesis |
| Q26829294 | Fibroblast growth factor 23 |
| Q92128918 | Fractional Excretion of Phosphate (FeP) Is Associated with End-Stage Renal Disease Patients with CKD 3b and 5 |
| Q54094991 | High calcium diet alleviates 5/6 nephrectomy-induced bone deteriorations of lumbar vertebrae in mice. |
| Q57217879 | Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease |
| Q38828902 | Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification |
| Q58701703 | Intestinal Phosphorus Absorption in Chronic Kidney Disease |
| Q90746960 | Kidney Disease Progression Does Not Decrease Intestinal Phosphorus Absorption in a Rat Model of Chronic Kidney Disease-Mineral Bone Disorder |
| Q55162820 | Lower serum calcium is independently associated with CKD progression. |
| Q39023147 | Management of phosphorus load in CKD patients. |
| Q89143763 | Medication Safety Principles and Practice in CKD |
| Q87499495 | Mineral metabolism: The perils of a falling PTH due to high dialysate calcium |
| Q36890341 | Nutrition in Cardioskeletal Health. |
| Q38161580 | Optimal use of phosphate binders in chronic kidney disease |
| Q39255870 | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. |
| Q92184944 | Oxidative stress contributes to vascular calcification in patients with chronic kidney disease |
| Q49908584 | Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease |
| Q38572880 | Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease. |
| Q36965142 | Phosphate Toxicity in CKD: The Killer among Us |
| Q36361143 | Phosphate binders affect vitamin K concentration by undesired binding, an in vitro study. |
| Q57213546 | Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD) |
| Q38202179 | Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles |
| Q31039292 | Phosphate binders in chronic kidney disease: a systematic review of recent data |
| Q39155279 | Phosphate binders in patients with chronic kidney disease. |
| Q55524819 | Phosphorus Balance in Adolescent Girls and the Effect of Supplemental Dietary Calcium. |
| Q37204047 | Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide |
| Q38673170 | Pro: Should phosphate binders be used in chronic kidney disease stage 3-4? |
| Q36104887 | Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. |
| Q88494286 | Rationale to reduce calcium intake in adult patients with chronic kidney disease |
| Q36746618 | Relationship of dietary phosphate intake with risk of end-stage renal disease and mortality in chronic kidney disease stages 3-5: The Modification of Diet in Renal Disease Study |
| Q57823250 | Renal association commentary on the KDIGO (2017) clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD |
| Q45335311 | Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference |
| Q64970894 | Role of Albumin Assay on Calcium Levels and Prescription of Phosphate Binders in Chronic Hemodialysis Patients. |
| Q35160399 | Serum vitamin D and parathyroid hormone profiles in patients with various stages of renal disease |
| Q34505136 | Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials |
| Q38229798 | Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study |
| Q90480569 | Small steps towards the potential of 'preventive' treatment of early phosphate loading in chronic kidney disease patients |
| Q92803503 | Strategies for Phosphate Control in Patients With CKD |
| Q47760167 | The Divalent Elements Changes in Early Stages of Chronic Kidney Disease |
| Q38584122 | The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder |
| Q38377286 | The challenge of controlling phosphorus in chronic kidney disease |
| Q36214854 | The demise of calcium-based phosphate binders-is this appropriate for children? |
| Q35218508 | The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease |
| Q37734160 | The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study |
| Q38244314 | The role of bone in CKD-mediated mineral and vascular disease |
| Q54081159 | The role of calcium and non calcium-based phosphate binders in chronic kidney disease. |
| Q38793054 | The role of phosphate in kidney disease |
| Q34337575 | The role of the gastrointestinal tract in phosphate homeostasis in health and chronic kidney disease |
| Q33835743 | The use of fibroblast growth factor 23 testing in patients with kidney disease |
| Q38958363 | Treating hyperphosphatemia - current and advancing drugs |
| Q39271483 | Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder |
| Q36466010 | Treatment of phosphate retention: The earlier the better? |
| Q89157892 | Twenty-Four-Hour Urine Phosphorus as a Biomarker of Dietary Phosphorus Intake and Absorption in CKD: A Secondary Analysis from a Controlled Diet Balance Study |
| Q46233386 | Urine Anion Gap to Predict Urine Ammonium and Related Outcomes in Kidney Disease |
Search more.